ERBB2 and breast cancer: In this study, the ER and PR positivity rates of male breast cancer could be over 90%, respectively; the HER2 positivity rate was 10.38%, the incidence of low-expression was 67.93%, and the incidence of ultra-low expression was 12.26%.